Uses for non-autologous mesenchymal stem cells

• US 6,355,239 B1
• Filed: 03/12/1999
• Issued: 03/12/2002
• Est. Priority Date: 03/13/1998
• Status: Expired due to Term

• Current Assignee: Mesoblast International Srl
• Original Assignee: Osiris Therapeutics Incorporated (Smith & Nephew PLC)
• Inventors: Bruder, Scott P., Mosca, Joseph D., McIntosh, Kevin R., Marshak, Daniel R.
• Primary Examiner(s): Nguyen, Dave T.
• Assistant Examiner(s): Shukla, Ram R.
• Application Number:
  US09/314,855
• Time in Patent Office: 1,096 Days
• Field of Search: 424/93.1, 435/325, 435/455, 435/2, 435/372, 623/16
• US Class Current: 424/93.1
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

Methods and devices using non-autologous mesenchymal stem cells comprising treating a recipient in need thereof with an effective amount of non-autologous mesenchymal stem cells, including methods and preparations for treating and regenerating connective tissue and enhancing bone marrow engraftment in an individual; and for using genetically engineered allogeneic human mesenchymal stem cells that carry within them genes of interest particularly for the expression of physiologically or pharmacologically active proteins in gene therapy for correction of genetic disorders or “rebuilding” proteins important in tissue repair.

Claims

1. A method for treating a human subject for promoting connective tissue growth, comprising:

treating a recipient human subject in need of connective tissue growth by administering a therapeutically effective amount of allogeneic mesenchymal stem cells to said recipient human subject, wherein said allogeneic mesenchymal stem cells are obtained from a donor human subject and wherein a step of MHC matching of said donor human subject to said recipient human subject is not employed prior to the administration of said allogeneic mesenchymal stem cells to the recipient human subject.

2. The method of claim 1 wherein the allogeneic human mesenchymal stem cells are recovered from human bone marrow and are administered to the recepient human subject in a cell preparation which is substantially free of blood cells.

3. The method of claim 2 wherein the cell preparation is administered in conjunction with a carrier for the cell preparation.

4. The method of claim 1 wherein the allogeneic mesenchymal stem cells are administered to generate bone formation.

5. The method of claim 1 wherein the allogeneic human mesenchymal stem cells are administered to treat or repair a connective tissue defect in the recepient human subject.

6. The method of claim 5 wherein the defect is a bone defect.

7. The method of claim 5 wherein the defect is a cartilage defect.

8. The method of claim 5 wherein the defect is a skeletal tissue defect.

9. The method of claim 5 wherein the allogeneic human mesenchymal stem cells are administered.

10. The method of claim 1 wherein the allogeneic human mesenchymal stem cells are administered systemically.

11. The method of claim 1 wherein the preparation is administered intravenously.

12. The method of claim 1 wherein the allogeneic human mesenchymal stem cells express incorporated genetic material of interest.